Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valsartan SCHEMBL29518879 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL8476946 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL24722321 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL678231 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL31532957 | 0.99 | AGTR1 (0.98) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL28804181 | 0.94 | AGTR1 (0.90) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL24224463 | 0.93 | AGTR1 (0.87) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL20257282 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL16482977 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL1828137 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813564-A | Synthetic refining method of valsartan | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-115160246-A | Process for recovering valsartan from valsartan mother liquor | 江苏新瑞药业有限公司 | 2022-10-11 | — | — | CN | claimed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | claimed |
| CN-116813564-B | Synthetic refining method of valsartan | 山东新时代药业有限公司 | 2026-02-24 | — | — | CN | disclosed |
| CN-116813564-A | Synthetic refining method of valsartan | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116813564-A | Synthetic refining method of valsartan | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230172854-A1 | A SOLID CO-AMORPHOUS DISPERSION OF VALSARTAN, A METHOD FOR SYNTHETIZING THE SAME AND A MEDICAL USE OF THE DISPERSION | UNIV HUMANISTYCZNO PRZYRODNICZY IM JANA DLUGOSZA W CZESTOCHOWIE (PL) | 2023-06-08 | — | — | US | disclosed |
| US-20230172854-A1 | A SOLID CO-AMORPHOUS DISPERSION OF VALSARTAN, A METHOD FOR SYNTHETIZING THE SAME AND A MEDICAL USE OF THE DISPERSION | UNIV HUMANISTYCZNO PRZYRODNICZY IM JANA DLUGOSZA W CZESTOCHOWIE (PL) | 2023-06-08 | — | — | US | disclosed |
| US-20230145207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230145207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-04-27 | — | — | US | disclosed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090226516-A1 | SARTAN COMPOSITIONS | PHARMA PASS II LLC (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009070241-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-7439261-B2 | Process for the preparation of valsartan and intermediates thereof | DIPHARMA S.P.A. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-7439261-B2 | Process for the preparation of valsartan and intermediates thereof | DIPHARMA S.P.A. (IT) | 2008-10-21 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1533305-A1 | A process for the preparation of valsartan and intermediates thereof | Dipharma S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | ACADVL, CPT1A, ADH5 | AGTR1 4497/4885LTB4R2 1600/4885ABCB11 3079/4885 |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | CD44, FUT6, MSN | AGTR1 2514/4885LTB4R2 4507/4885ABCB11 581/4885 |
| US-20230172854-A1 | A SOLID CO-AMORPHOUS DISPERSION OF VALSARTAN, A METHOD FOR SYNTHETIZING THE SAME AND A MEDICAL USE OF THE DISPERSION | ACE2, ACE, AGTR2 | AGTR1 6/4885LTB4R2 1817/4885ABCB11 1051/4885 |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | AGTR1, AGTR2, ADRB1 | AGTR1 1/4885LTB4R2 87/4885ABCB11 265/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | AGTR1 8/4885LTB4R2 433/4885ABCB11 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.